Antibody Fragments Used in Pre-Clinical Pancreatic Cancer Imaging
By MedImaging International staff writers Posted on 11 Oct 2016 |
Image: Researchers performing a procedure using antibody fragments (Photo courtesy of Memorial Sloan Kettering Cancer Center).
Researchers have shown that certain antibody fragments can be coupled with Zirconium, a Copper-based PET imaging agent, and a fluorescent imaging agent without impacting immunoreactivity, to target bladder and pancreatic cancer.
The research results indicated that rapid immunoPET (Positron Emission Tomography) or immunofluorescent imaging could be used to provide imaging results within one day, faster than other current methods.
The researchers from the Memorial Sloan Kettering Cancer Center (MSK; New York, NY, USA) produced the F(ab')2 antibody fragments from MabVax Therapeutics’ (San Diego, CA, USA) HuMab-5B1 antibodies for use as a PET imaging agent, and as a radio-immunotherapy agent. MabVax Therapeutics specializes in developing and producing antibody-based clinical-stage oncology drugs.
David Hansen, CEO of MabVax Therapeutics, said, "We are grateful to Jason S. Lewis, PhD and his team for their continued pioneering work using the HuMab-5B1 platform. They are taking important steps in expanding the clinical utility of our HuMab-5B1 antibody, including (1) demonstrating that smaller fragments of our full-length antibody could provide significant advantages in speeding tumor imaging, (2) demonstrating the utility of our full length antibody with a new radio-immunotherapy approach, (3) helping MabVax to evaluate additional CA19-9 expressing cancers for which our antibody development program may have utility beyond our current focus on pancreatic cancer, and (4) completing investigations supporting our radio-immunotherapy product for which we plan to submit an Investigational New Drug Application later this year."
Related Links:
Memorial Sloan Kettering Cancer Center
MabVax Therapeutics
The research results indicated that rapid immunoPET (Positron Emission Tomography) or immunofluorescent imaging could be used to provide imaging results within one day, faster than other current methods.
The researchers from the Memorial Sloan Kettering Cancer Center (MSK; New York, NY, USA) produced the F(ab')2 antibody fragments from MabVax Therapeutics’ (San Diego, CA, USA) HuMab-5B1 antibodies for use as a PET imaging agent, and as a radio-immunotherapy agent. MabVax Therapeutics specializes in developing and producing antibody-based clinical-stage oncology drugs.
David Hansen, CEO of MabVax Therapeutics, said, "We are grateful to Jason S. Lewis, PhD and his team for their continued pioneering work using the HuMab-5B1 platform. They are taking important steps in expanding the clinical utility of our HuMab-5B1 antibody, including (1) demonstrating that smaller fragments of our full-length antibody could provide significant advantages in speeding tumor imaging, (2) demonstrating the utility of our full length antibody with a new radio-immunotherapy approach, (3) helping MabVax to evaluate additional CA19-9 expressing cancers for which our antibody development program may have utility beyond our current focus on pancreatic cancer, and (4) completing investigations supporting our radio-immunotherapy product for which we plan to submit an Investigational New Drug Application later this year."
Related Links:
Memorial Sloan Kettering Cancer Center
MabVax Therapeutics
Latest Nuclear Medicine News
- New PET Biomarker Predicts Success of Immune Checkpoint Blockade Therapy
- New PET Agent Rapidly and Accurately Visualizes Lesions in Clear Cell Renal Cell Carcinoma Patients
- New Imaging Technique Monitors Inflammation Disorders without Radiation Exposure
- New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access
- New Radiotheranostic System Detects and Treats Ovarian Cancer Noninvasively
- AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging
- Early 30-Minute Dynamic FDG-PET Acquisition Could Halve Lung Scan Times
- New Method for Triggering and Imaging Seizures to Help Guide Epilepsy Surgery
- Radioguided Surgery Accurately Detects and Removes Metastatic Lymph Nodes in Prostate Cancer Patients
- New PET Tracer Detects Inflammatory Arthritis Before Symptoms Appear
- Novel PET Tracer Enhances Lesion Detection in Medullary Thyroid Cancer
- Targeted Therapy Delivers Radiation Directly To Cells in Hard-To-Treat Cancers
- New PET Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Algorithm Predicts Prostate Cancer Recurrence in Patients Treated by Radiation Therapy
- Novel PET Imaging Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Ultrafast Laser Technology to Improve Cancer Treatment